Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Colomer

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Breast Cancer Research and Treatment|September 29, 2007
Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75Teresa Puig, Alejandro Vázquez-Martín, Joana Relat, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 13, 2024
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyRamon Colomer, Blanca González-Farré, Ana Isabel Ballesteros, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 21, 2024
The role of the CXCL12/CXCR4 axis in the immunotherapy of non-small cell lung cancerJacobo Rogado, Fernando Pozo, Kevin Troule, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 24, 2019
A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancerVilma Pacheco-Barcia, Rebeca Mondéjar Solís, Talya France, et al.
Cancer|October 11, 2007
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective studyRamon Colomer, Antonio Llombart-Cussac, Belen Lloveras, et al.
Molecular Oncology|August 9, 2014
Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trialMiguel Quintela-Fandino, Maria J Bueno, Luis Lombardia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Novel Inhibitors of Fatty Acid Synthase with Anticancer ActivityTeresa Puig, Carlos Turrado, Bellinda Benhamú, et al.
Current Oncology (Toronto, Ont.)|October 28, 2025
Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung CancerPaloma Galera, Antía Iglesias-Beiroa, Berta Hernández-Marín, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 23, 2011
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancerCristina Grávalos, Carlos Gómez-Martín, Fernando Rivera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well toleratedBrian Leyland-Jones, Ramon Colomer, Maureen E Trudeau, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Breast Cancer Research and Treatment|September 29, 2007
Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75Teresa Puig, Alejandro Vázquez-Martín, Joana Relat, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 13, 2024
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyRamon Colomer, Blanca González-Farré, Ana Isabel Ballesteros, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 21, 2024
The role of the CXCL12/CXCR4 axis in the immunotherapy of non-small cell lung cancerJacobo Rogado, Fernando Pozo, Kevin Troule, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 24, 2019
A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancerVilma Pacheco-Barcia, Rebeca Mondéjar Solís, Talya France, et al.
Cancer|October 11, 2007
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective studyRamon Colomer, Antonio Llombart-Cussac, Belen Lloveras, et al.
Molecular Oncology|August 9, 2014
Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trialMiguel Quintela-Fandino, Maria J Bueno, Luis Lombardia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Novel Inhibitors of Fatty Acid Synthase with Anticancer ActivityTeresa Puig, Carlos Turrado, Bellinda Benhamú, et al.
Current Oncology (Toronto, Ont.)|October 28, 2025
Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung CancerPaloma Galera, Antía Iglesias-Beiroa, Berta Hernández-Marín, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 23, 2011
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancerCristina Grávalos, Carlos Gómez-Martín, Fernando Rivera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well toleratedBrian Leyland-Jones, Ramon Colomer, Maureen E Trudeau, et al.
Pageof 8